Immune dysfunction is well documented during tumor progression and likely contributes to tumor immune evasion. CD8 1 cytotoxic T lymphocytes (CTLs) are involved in antigen-specific tumor destruction and CD4 1 T cells are essential for helping this CD8 1 T cell-dependent tumor eradication. Tumors often target and inhibit T-cell function to escape from immune surveillance. This dysfunction includes loss of effector and memory T cells, bias towards type 2 cytokines and expansion of T regulatory (Treg) cells. Curcumin has previously been shown to have antitumor activity and some research has addressed the immunoprotective potential of this plant-derived polyphenol in tumor-bearing hosts. Here we examined the role of curcumin in the prevention of tumor-induced dysfunction of T cell-based immune responses. We observed severe loss of both effector and memory T-cell populations, downregulation of type 1 and upregulation of type 2 immune responses and decreased proliferation of effector T cells in the presence of tumors. Curcumin, in turn, prevented this loss of T cells, expanded central memory T cell (T CM )/effector memory T cell (T EM ) populations, reversed the type 2 immune bias and attenuated the tumor-induced inhibition of T-cell proliferation in tumor-bearing hosts. Further investigation revealed that tumor burden upregulated Treg cell populations and stimulated the production of the immunosuppressive cytokines transforming growth factor (TGF)-b and IL-10 in these cells. Curcumin, however, inhibited the suppressive activity of Treg cells by downregulating the production of TGF-b and IL-10 in these cells. More importantly, curcumin treatment enhanced the ability of effector T cells to kill cancer cells. Overall, our observations suggest that the unique properties of curcumin may be exploited for successful attenuation of tumor-induced suppression of cell-mediated immune responses.
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2 double-negative immature thymocytes, causes a decline in CD4 1 and CD8 1 effector populations in secondary immune organs and in circulation, weakens cellular defense mechanisms and induces thymic atrophy. 4 Moreover, there is evidence for augmented apoptosis of T cells among cancer patients and mice with experimental tumors. 5 Recent evidence from several laboratories, including our own, suggests that tumors may inhibit the development of an effective antitumor immune response either by directly inducing T-cell apoptosis or by sensitizing T lymphocytes to activation-induced cell death. [6] [7] [8] There is evidence of increased apoptosis among CD8 1 T cells in peripheral blood lymphocytes from cancer patients and animal models. 4 These alterations correlate with the severity of the disease and with poor survival. Thus, tumor-induced immune suppression can add to the spread of the disease and create a barrier to immunotherapeutic interventions. Tumors often contribute to a diminished proportion of effector T cells producing interferon (IFN)-c and IL-2, thus decreasing the T helper 1 (Th1)-type immune response in the tumor-bearing host. [9] [10] [11] IL-2 is a key cytokine in the regulation of the survival and expansion of peripheral T-cell populations, and IFN-c is primarily responsible for activating and regulating the development and persistence of cytotoxic T lymphocytes (CTLs).
12 CD8 1 T cells secreting IFN-c represent the effector Tc1 population, known to be essential for tumor eradication by cell-mediated immunity. 13, 14 In cancer patients there is a shift from a type 1-mediated CD4
1 T-cell response, which produces IFN-c that is critical for the development of effective antitumor immunity, to a type 2 cytokine response (IL-4, IL-5 and IL-10), which typically mediates humoral immunity. 15 Patients rendered disease free by primary tumor excision and/or immunotherapy revert to a predominance of IFN-c-producing type 1 CD4
1 T cells, suggesting that the tumor environment may be skewing the immune system towards a type 2 response. 16 A growing tumor can evade immune surveillance by several mechanisms, 17, 18 including manipulation of the microenvironment in a manner to induce negative regulation of immune responses within the host. These negative regulatory mechanisms include induction of tumor-specific T-cell tolerance mediated by T-regulatory (Treg) cells, 19 a subset of CD4 1 lymphocytes. Treg cells are a family of suppressor T cells which are further divided into two groups: thymicderived 'naturally occurring' Treg cells and induced/adaptive Treg cells generated extra thymically under certain conditions, including autoimmune diseases, transplantation tolerance and tumor immunity. [20] [21] [22] Accumulating evidence suggests that Treg cells induced in tumor microenvironments are highly immunosuppressive. 23 Relevant to antitumor immunotherapy, experimental models have shown that removal of Treg cells modifies the immune response to tumors. 24 In mouse models, depletion of Treg cells with anti-CD25 antibody has been shown to enhance antitumor activity. 25 It has also been suggested that the production of immunosuppressive cytokines by Treg cells is an important strategy employed by the growing tumor to evade immune surveillance. 26, 27 Thus, therapeutic interventions designed to prevent tumorinduced downregulation of cell-mediated immune responses will be helpful to enhance antitumor immunity. In the current study, we characterized the mechanisms of tumor-induced immunosuppression and the role of curcumin (the major pigment of ground rhizome Curcuma longa, a known antioxidant with proven antitumor activity) 28 in the prevention of immunosuppression caused by a progressing tumor. Reports of the immunomodulatory power of curcumin in tumor-bearing hosts are scarce. We recently demonstrated that curcumin reduced the overall systemic toxicity, while effectively lowering the tumor burden, and prevented tumor-induced T-cell depletion. [28] [29] [30] This is the first time we are reporting the intricate mechanism of curcumin-induced immune restoration in tumor-bearing animals, and our results suggest that curcumin can prevent tumorinduced immunosuppression via restoration of effector T-cell populations, normalization of the cytokine profile and downregulation of Treg cell activity.
RESULTS
Curcumin restores tumor-induced depletion of T cells in tumorbearing hosts
To determine the effects of neoplastic conditions on the host's immune system, we used mice inoculated with Ehrlich's ascites carcinoma (EAC, a murine mammary carcinoma cell line). Lymphocytes from the peripheral blood, draining lymph nodes and tumor sites (tumor-infiltrating lymphocytes (TIL)) were isolated from tumorbearing mice and compared with those of normal mice ( Figure 1a ). Analysis of circulating, lymph-node and tumor-site T-cell subpopulations of tumor-bearing mice revealed that both the helper T lymphocyte (CD4 1 ) and the CTL (CD8 1 ) populations were diminished in comparison to that of normal counterparts (Figure 1a) . We have previously shown that curcumin induces apoptosis in human breast cancer and ascites carcinoma cells. [26] [27] [28] Here we observed that administration of curcumin (50 mg/kg) to tumor-bearing animals prevented tumor-induced depletion of circulating and lymph-node T-cell populations and increased the number of CD4 1 and CD8 1 T cells present at the tumor site (Figure 1b) .
Curcumin restores central memory T cell (T CM ) and effector memory T cell (T EM ) populations in tumor-bearing hosts The memory T-cell pool functions as a dynamic repository of antigenexperienced T lymphocytes that accumulate over the lifetime of the individual. Thus, our observation of tumor-induced depletion of CD4 1 and CD8 1 T-cell populations prompted us to further study the status of the memory T-cell population. Recent studies indicate that memory T lymphocytes contain distinct T CM and T EM populations, characterized by distinct homing capacity and effector functions. 31 With this in mind, we characterized the effect of tumor burden on memory T-cell populations. Central and memory T cells were characterized by monitoring the surface expression of CD44 and CCR7 among CD4
1 and CD8 Curcumin normalizes Th1/Tc1-type cytokine-producing effector T-cell populations in tumor-bearing hosts We next analyzed the capacity of lymphocytes of normal and tumorbearing mice to produce cytokines after phorbol-12-myristate-13-acetate/ionomycin activation ( Figure 3a ). We observed a reduced proportion of Th1/Tc1-type cytokine (IFN-c)-secreting CD4 1 and CD8 1 T cells ( Figure 3b ) and an increased proportion of Th2/Tc2-type cytokine (IL-4)-secreting CD4 1 and CD8 1 T cells (Figure 3c ) within the peripheral circulation, lymph nodes and tumor sites of tumor-bearing mice in comparison to their normal counterparts. Administration of curcumin to the tumor-bearing mice, however, restored the cytokine expression in the circulation, lymph-node and tumor-site lymphocytes to normal levels (Figure 3b and c) . Overall, we observed that tumor-bearing hosts have a Th2-type cytokine bias in the peripheral circulation, lymph nodes and tumor sites, which was essentially reversed by curcumin (Figure 3d ).
Curcumin prevents tumor-induced downregulation of T-cell proliferation
Our results have demonstrated the loss of effector T-cell activity due to a decrease in the percentage of effector/memory T cells and an increase in Th2-type cytokines in tumor-bearing animals. To determine if tumors also influence the proliferative capacity of effector T cells in response to a T-cell antigen receptor stimulus, CD3
1 T cells from normal, tumor-bearing or curcumin-fed tumor-bearing mice were isolated and loaded with 5-(and-6)-carboxyfluorescein succinimidyl ester (CFSE). Data presented in Figure 4 show that T cells from healthy and curcumin-fed mice proliferated in response to anti-CD3 and anti-CD28 antibodies. However, T cells from tumor-bearing mice failed to proliferate in response to anti-CD3 and anti-CD28 antibodies. Interestingly, curcumin prevented tumor-induced downregulation of T-cell proliferation (Figure 4 ), suggesting that apart from inhibiting tumor-induced loss of effector T-cell activity, curcumin also restored T-cell proliferative capacity.
Curcumin prevents tumor-induced augmentation of CD4 1 CD25 1 FoxP3 1 Treg cell populations in tumor-bearing hosts
It is well known that the loss of Th1-type effector activity is associated with the upregulation of Treg suppressor activity in tumor-bearing animals. 32 Tregs were flowcytometrically characterized by the expression of FoxP3 in CD4
1 CD25 1 T cells as shown in Figure 5a . The proportions of CD4 1 CD25 1 FoxP3 1 (markers of Treg cells in mice) 33 Treg cells were found to be elevated in the peripheral circulation, lymph nodes and tumor sites of tumor-bearing mice when compared to that of normal mice (Figure 5b 
Curcumin potentiates T cell-mediated tumor-cell killing in vitro
To test whether curcumin-mediated protection of effector T-cell populations influences immune-mediated tumor elimination, peripheral T cells from healthy mice were exposed to cell-free supernatants from tumor cells treated with or without curcumin and then cocultured with EAC cells. After 24 h of incubation, apoptosis of the EAC cells was measured by Annexin-V/7-amino-actinomycin D (7-AAD) binding followed by flow cytometry. We observed that naive T cells were able to kill tumor cells more efficiently than T cells pre-treated with tumor supernatants (Figure 7a) . Interestingly, T cells cultured with supernatant from curcumin-treated tumor cells were more efficient at inducing tumor-cell killing than T cells cultured with supernatant from untreated tumor cells (Figure 7a ). Since T cell-mediated cancer cell killing is mediated by several proteolytic proteins secreted by CD8
1 T cells, we measured the levels of granzyme and perforin in CD8 1 T cells. Figure 7b shows that curcumin inhibited the tumormediated reduction of granzyme and perforin in CD8 1 cytotoxic T cells. These data indicate that curcumin not only prevents tumorinduced loss of effector T-cell populations but also contributes to immune-mediated tumor-cell killing.
Curcumin
Curcumin inhibits tumor growth and increases survival rates of tumor-bearing mice Our results have indicated that curcumin restores the suppressed immune system found in tumor-bearing hosts. We further attempted to analyze this immunomodulatory capacity of curcumin in terms of tumor regression and survival rates of tumor-bearing animals, using 10 individual mice in each group. As depicted in Figure 7c , we observed that EAC cells grew up to 390 million in untreated mice but the number of EAC cells was reduced to 20 million in curcumin-treated mice. In support of these data, the survival rate in the untreated group was only 50% (Figure 7d) , while in the curcumintreated group the survival rate increased to 96%. Thus, administering curcumin to tumor-bearing mice resulted in both tumor regression and improved survival rates.
DISCUSSION
In order to establish itself, a growing tumor often induces severe immunosuppression, which almost always abolishes effective cellmediated immune responses of the host. The mechanisms of tumorinduced suppression of cell-mediated immunity include a decline in CD8 1 ) accompanied by a loss of effector T-cell activity and downregulation of Th1-type cytokine responses, along with augmentation of Th2-type cytokine responses. This shift from a Th1-to a Th2-type response also contributes to the decreased activity of effector CTLs. 36 Another important reason for the failure of tumor immune surveillance is the augmentation of immunosuppressive Treg cells. 37 In accordance with previous findings, our results depicted a reduction in the number of effector and memory T cells and a shift from a Th1-to a Th2-type response in tumor-bearing hosts, along with elevated levels of Treg cells. Curcumin, in turn, was found to prevent these tumor-induced alterations of the immune system, thereby strengthening the antitumor response of the tumor-bearing host. CD4 1 T cells appear to be critical for the promotion of memory CD8 1 T-cell responses, 38 although CD8 1 T cells are the effector cells more commonly associated with tumor rejection. 39 Tumor insult 12 By contrast, Th2-mediated immunity (IL-4 is the prototypical Th2 cytokine) is thought to favor tumor growth, both by promoting angiogenesis and by inhibiting cell-mediated immunity and subsequent tumor-cell killing. 40 We observed that curcumin not only restored the activated/effector CD4 1 and CD8 1 T-cell populations in the tumor-bearing host but also increased the percentage of these cells at the tumor site. TILs play a critical role in detection and eradication of tumor cells; 41 thus, curcumin-induced augmentation of TILs can help to restore appropriate antitumor immune responses in the host. Curcumin administration increased the proportion of IFNc-secreting CD4 1 and CD8 1 T cells in the circulation and at the tumor site of tumor bearers, clearly indicating that it prevents the depletion of Th1 cells in these organs with a corresponding decrease in the type 2 bias. Interestingly, curcumin also reversed tumor-induced inhibition of effector T-cell proliferation.
Tumor-bearing hosts are known to have a high proportion of CD4 1 CD25 1 FoxP3 1 Treg cells (FoxP3 is the transcription factor exclusively produced in Treg cells). 42 Treg cells produce TGF-b and IL-10, two immunosuppressive cytokines, to downregulate the Th1-type response. 43 Apart from their suppressive activity, Treg cells compete with other T cells for IL-2, an important T-cell growth factor, thereby reducing the availability of IL-2 for other T cells. 44 Interestingly, our results further demonstrated that curcumin administration not only downregulates Treg suppressive activity but also inhibits its augmentation in tumor-bearing mice.
Reports of the immunomodulatory effects of curcumin indicate that it favors a Th2-type response, 45 but there are several reports which indicate that curcumin can augment tumor eradication by reinstating T-cell responses. 46 Gertshe et al. 47 also showed that curcumin upregulates IFN-c mRNA expression, indicating that the effect of curcumin on Th1 responses is not solely inhibitory. In line with these observations, our data indicate that curcumin administration enhances the antitumor immune response of T cells in tumor-bearing hosts. Interestingly, normal T cells pre-incubated with curcumin failed to show such immunostimulatory effects. Previously, we have shown that curcumin can induce tumor-cell killing, lower systemic toxicity and neutralize oxidative stress in the immune system, resulting in Tcell protection. [28] [29] [30] Here we report that curcumin reduced the levels of TGF-b and IL-10 in Treg cells and reduced the number of Treg cells in the tumor-bearing hosts. Complex interactions between various signals produced by the tumor and by curcumin ultimately result in augmentation of Th1/Tc1-type responses in the tumor-bearing host. The immunoprotective role of curcumin was further strengthened when we found that curcumin potentiates T cell-mediated tumor-cell killing. Thus, the observed protective effects of curcumin on Th1 and Tc1 populations in the tumor-bearing mice may be attributed to the fact that curcumin reduces Treg cell populations and inhibits TGF-b and IL-10 production from Treg cells, finally reducing tumor burden. Taken together, these results and the results of experiments with human samples indicate that curcumin may protect effector T cells in tumor-bearing hosts, thereby supporting the use of curcumin as a pharmacologically and immunologically safe anticancer drug. Curcumin is currently undergoing clinical testing, and although detailed reports of the results in human cancer patients are still Curcumin restores antitumor immune response S Bhattacharyya et al 313 unavailable, the current study provides some much needed insight into the effects of this antitumor agent on the immune system. and Indian laws on 'Protection of Animals' under the supervision of authorized investigators. Mice were divided into four groups of 10 animals each, including normal (non-tumor-bearing), tumor-bearing (which were intraperitoneally injected with 1310 5 exponentially grown EAC), curcumin-treated (non-tumor-bearing) and curcumin-treated tumor-bearing. Curcumin (50 mg/kg body weight every alternate day; treatment started 7 days after tumor inoculation) was fed orally.
MATERIALS AND METHODS
Treatment of animals
Cell culture and experiments
At day 21 of tumor inoculation, the carcinoma cells were isolated aseptically from the peritoneal cavity of tumor-bearing mice. 27, 28 The isolated cells were then subjected to negative selection using anti-CD3 and anti-CD16 antibody-coated microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany). More than 98% of the CD16-/CD3-negative cells were morphologically characterized as EAC by Wright staining and viability was assessed to be .95% by trypan blue dye exclusion. Peripheral blood, collected from mice, was centrifuged over Ficoll-Hypaque (Amersham Pharmacia, Uppsala, Sweden) density gradient to obtain total lymphocytes. T cells were purified by positive selection from total lymphocytes using microbeads coated with mouse anti-CD3 antibodies. Cells ware maintained in complete RPMI 1640 medium at 37 uC in humidified incubator containing 5% CO 2 . 29, 30 TILs from ascites carcinoma were isolated by positive selection using anti-CD3-coated microbeads. EAC cells were incubated for 48 h in the presence or absence of 10 mM curcumin; supernatant was freed from cellular components and used in a 1 : 1 ratio with RPMI 1640 media to study the effect of tumor supernatant on T cells. To determine the effects of curcumin pre-treatment on immunemediated tumor-cell killing, normal T cells were co-incubated with tumor cells for 24 h (effector/target cell ratio of 1 : 10).
Phenotypic analysis of Treg and memory T cells
For the quantification of Treg cells, T cells from the peripheral blood and tumor sites were labeled with peridinin chlorophyll protein complex (PerCP)-conjugated CD4, FITC-conjugated CD25 and phycoerythrin (PE)-conjugated FoxP3 antibodies (BD Bioscience, San Jose, CA, USA). Cells were then analyzed with a FACS Calibur (BD Bioscience) equipped with a 488-nm argon laser light source, a 530-nm band pass filter for FITC fluorescence and a 575-nm band pass filter for phycoerythrin (PE fluorescence. Cells were properly acquired, gated and analyzed using CellQuest Software (BD Bioscience). For the analysis of memory T cells, cells were labeled with PerCP-conjugated CD4 or CD8 monoclonal antibodies and then with PE-conjugated CCR7 and FITC-conjugated CD44 antibodies (for the determination of T CM and T CM populations; BD Bioscience). Cells were then analyzed by FACS.
Proliferation and apoptosis assay
The CD3 1 cells were loaded with CFSE (Molecular Probes, Eugene, OR, USA) and proliferation was induced by stimulating CD3
1 cells (1310 6 cells/ml) with cross-linked anti-CD3 antibodies and soluble anti-CD28 antibodies for 72 h. Dilution of CFSE fluorescence as a marker of cell proliferation was assayed by flow cytometry. For the determination of cell death, tumor cells were labeled with 7-AAD and Annexin-V-PE (BD Bioscience) and analyzed by flow cytometry. Annexin-V 1 /7-AAD 1 cells were considered apoptotic.
29,30
Detection of intracellular cytokines by flow cytometry T cells were stimulated with phorbol-12-myristate-13-acetate (10 ng/ml) and ionomycin (1 mM), and transport of newly synthesized cytokines from the Golgi apparatus was blocked with 10 mg/ml Brefeldin A (Sigma, St Louis, MO, USA). After incubation for 4 h at 37 uC, cells were washed with phosphate-buffered saline and half of the cells were labeled with PerCP-CD4/FITC-CD8 or PerCP-CD4/FITC-CD25 antibodies. Cells were permeabilized with saponin and intracellular TGF-b, IL-10, IFNc, IL-2 and IL-4 (10 ml, dilution 1 : 30; BD Bioscience) were labeled with PE-/FITC-tagged antibodies and were analyzed by FACS.
Statistical analysis
Values are shown as standard error of mean (SEM) except when otherwise indicated. Data were analyzed and, when appropriate, significance of the differences between mean values was determined by Student's t-test. Results were considered significant at P,0.05.
